OPPI and NIPER Raebareli partner to boost pharma research and talent

Scholarships, research grants and industry mentorship framework aim to strengthen India’s pharma R&D ecosystem

Bayer sets world record for maternal nutrition advocacy

India continues to face a major maternal nutrition challenge, with nearly 60% of women affected by anaemia and more than 70% experiencing calcium deficiency

Dr. Jitendra Singh urges industry to step up R&D collaboration

Minister highlights RDI fund, private participation in space and nuclear sectors, and calls for faster reforms to improve ease of research in India

India’s Dapagliflozin Moment: Why USFDA’s generic greenlight wave matters

In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga

Halozyme strikes global deal with Vertex to expand Hypercon drug delivery technology

The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets

RoosterBio taps MineBio to supercharge hMSC & exosome solutions in China

Johnson & Johnson unveils Varipulse Pro in Europe for faster & safer heart procedures

The new device promises faster, more efficient cardiac procedures while maintaining the safety and effectiveness clinicians expect

Lupin wins USFDA nod for generic Dapagliflozin tablets

Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market

Aurobindo gets USFDA approval for Dapagliflozin with 180-day exclusivity

Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size

Aurobindo Pharma wins USFDA approval for generic Xigduo XR

Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually